- Home
- GUG vs RIGL Comparison
GUG vs RIGL Comparison
Compare GUG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- RIGL
- Stock Information
- Founded
- GUG 2021
- RIGL 1996
- Country
- GUG United States
- RIGL United States
- Employees
- GUG N/A
- RIGL N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GUG Finance
- RIGL Health Care
- Exchange
- GUG Nasdaq
- RIGL Nasdaq
- Market Cap
- GUG 492.1M
- RIGL 486.4M
- IPO Year
- GUG N/A
- RIGL 2000
- Fundamental
- Price
- GUG $15.19
- RIGL $20.13
- Analyst Decision
- GUG
- RIGL Buy
- Analyst Count
- GUG 0
- RIGL 5
- Target Price
- GUG N/A
- RIGL $34.80
- AVG Volume (30 Days)
- GUG 108.9K
- RIGL 344.2K
- Earning Date
- GUG 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- GUG 9.67%
- RIGL N/A
- EPS Growth
- GUG N/A
- RIGL N/A
- EPS
- GUG N/A
- RIGL 0.22
- Revenue
- GUG N/A
- RIGL $157,374,000.00
- Revenue This Year
- GUG N/A
- RIGL $48.98
- Revenue Next Year
- GUG N/A
- RIGL $14.43
- P/E Ratio
- GUG N/A
- RIGL $90.91
- Revenue Growth
- GUG N/A
- RIGL 21.65
- 52 Week Low
- GUG $12.71
- RIGL $7.48
- 52 Week High
- GUG $15.06
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GUG 51.56
- RIGL 58.75
- Support Level
- GUG $14.81
- RIGL $15.50
- Resistance Level
- GUG $15.06
- RIGL $18.25
- Average True Range (ATR)
- GUG 0.17
- RIGL 1.28
- MACD
- GUG 0.04
- RIGL 0.43
- Stochastic Oscillator
- GUG 85.42
- RIGL 92.32
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.